Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Mirion Technologies, Inc.

Stifel Nicolaus analyst James Condulis maintained a Buy rating on Mirum Pharmaceuticals today and set a price target of $136.00. According to TipRa...

Stifel Nicolaus Sticks to Its Buy Rating for Mirum Pharmaceuticals (MIRM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mirum Pharmaceuticals (MIRM) and Encompass Health (E...

Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC)

Mirrabooka Investments Ltd ( ($AU:MIR) ) has shared an update. Mirrabooka Investments has reported an estimated pre-tax net tangible asset backing ...

Mirrabooka Reveals July Pre-Tax NTA and Dividend Adjustments

MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. On July 27, 2026, MIRA Pharmaceuticals received notice from Nasdaq that its common s...

MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice

Mirrabooka Investments Ltd ( ($AU:MIR) ) has shared an announcement. Mirrabooka Investments Limited has scheduled a shareholder webcast presentatio...

Mirrabooka to Present Full-Year Results in Shareholder Webcast

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Mirion Technologies (MIR), Werner Enterprise...

Analysts’ Opinions Are Mixed on These Industrial Goods Stocks: Mirion Technologies (MIR), Werner Enterprises (WERN) and Veralto Corporation (VLTO)

An update from Mirrabooka Investments Ltd ( ($AU:MIR) ) is now available. Mirrabooka Investments Limited has reported an estimated pre-tax net tang...

Mirrabooka Updates Estimated Pre-Tax NTA Backing Per Share

B. Riley Securities analyst initiated coverage with a Buy rating on Mirion Technologies yesterday and set a price target of $29.00. The company’s s...

Mirion Technologies (MIR) Gets a Buy from B. Riley Securities

Mirum Pharmaceuticals ($MIRM) announced an update on their ongoing clinical study. Mirum Pharmaceuticals, Inc. is running a Phase 1 trial called “A...

Mirum Advances New Drug Candidate With Fresh Phase 1 Study Update

In a report released today, Jeff Grampp from Northland Securities maintained a Buy rating on Mirion Technologies, with a price target of $29.00. Ac...

Northland Securities Reaffirms Their Buy Rating on Mirion Technologies (MIR)

Mirrabooka Investments Ltd ( ($AU:MIR) ) has provided an update. Mirrabooka Investments Limited reported an estimated pre-tax net tangible asset ba...

Mirrabooka posts updated pre-tax NTA backing versus share price

MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an announcement. On July 10, 2026, MIRA Pharmaceuticals reported positive preclinical results for...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIR	$15.71	+4.59%	2.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIR	$15.71	+4.6%	2.88M
3
4
5
6

MIR

MIR

Get Mirion Technologies, Inc. Data in Excel

Get Mirion Technologies, Inc. Data in Excel